BPC 157 protocols vary based on injury type, route of administration, formulation, and treatment goal
In this process, Efg1 plays an important role, although it is affected by hypoxia and the hosts immune status [11, 12]
Starting Dose 20 units (0.6mg) Form Injectable vial (5mL, 3mg/mL, 15mg total) Dosing Protocol 20 units subcutaneous injection daily, Monday to Friday
Three factors are especially critical for the KLOW blend because they specifically affect GHK-Cu: protect the copper peptide from light to avoid photo-oxidation, keep the pH in the optimal range of about 5.0 to 6.5 and avoid pH extremes, and minimize freeze-thaw cycles, as these favor aggregation and oxidation
BPC-157 has been studied in models involving the stomach, gastric juice, and intestinal tissue